

MONDAY 15th April 2024 – Spaces at the Spine, Liverpool, L7 3FA, UK			
09:00	Registration open for CEP and Congress Delegates – light breakfast items (fruit and pastries) will be available.		
11:00 – 12:00	BTS Scientific Subcommittee Meeting (SSC members only) Wolfson Lecture Theatre		
Continuing Education Programme (Space 1&2 – Level 13)			
Title – Endocrine Disruption			
09:30 – 9:40	Introduction <i>Chairs: Dr Nathan Goldsmith (Exponent) and Mr Sean O'Halloran (Labcorp)</i>		
09:40 – 10:05	Overview of Endocrine Disruption – Dr Hollie Blunt (Sequani Ltd)		
10:05 – 10:30	Thyroid Tox and Mode of Action – Dr Richard Haworth (Rosetta path)		
10:30 – 10:50	<i>Refreshments</i>		
10:50 – 11:15	EAS (estrogen-androgen-steroidogenesis) modalities – Dr Emily Richmond (Exponent)		
11:15 – 11:40	Endocrine disruption and ecotoxicology - Dr Emma Danby (Labcorp)		
11:40 – 11:55	Summary Discussion <i>Chairs: Dr Nathan Goldsmith (Exponent) and Mr Sean O'Halloran (Labcorp)</i>		
11:55 – 12.30	<i>Lunch (The Axis – Level 13; The Atrium – Level 12), & Trade Exhibition (Spaces 7, 8 & 9)</i>		
Congress Programme			
12:30 – 12:45	Congress Welcome (Space 1&2 – Level 13) BTS President: Professor Brian Lake (University of Surrey)		
12:45 – 13:30	Plenary Lecture: Prof. Frank Kelly (Imperial College London) <i>Air Pollution and Public Health: emerging hazards and improved understanding of risk.</i> <i>Chair: Prof. Brian Lake</i> (University of Surrey)		
13:30 – 14:30	BTS AGM		
14.30 – 15.00	<i>Refreshments (The Axis – Level 13; The Atrium – Level 12), Posters & Trade Exhibition (Spaces 7, 8 & 9)</i>		
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> <p>Symposium 1 (Space 1&2 – Level 13): <i>In silico</i> paths to chemical safety assessment <i>Chairs: Dr Ovnair Sepai (RSC Tox/UK HSA) and Prof. Andreas Bender (BTS/Cambridge University/Pangea Botanica)</i> [Collaboration between the Computational and In Silico Toxicology Speciality Section and RSC Toxicology Group]</p> </td> <td style="width: 50%; padding: 5px;"> <p>Symposium 2 (Space 4&5 – Level 12): Female Reprotox Regulatory Needs: from <i>in vivo</i> to NAM developments <i>Organised by: Dr Miriam Jacobs (UK HSA)</i> <i>Chairs: Dr Matt Van de Pette (UK HSA) and Ms Gabrielle Oxley (MRC Toxicology Unit)</i> [Hosted by Regulatory Toxicology Speciality Section]</p> </td> </tr> </table>	<p>Symposium 1 (Space 1&2 – Level 13): <i>In silico</i> paths to chemical safety assessment <i>Chairs: Dr Ovnair Sepai (RSC Tox/UK HSA) and Prof. Andreas Bender (BTS/Cambridge University/Pangea Botanica)</i> [Collaboration between the Computational and In Silico Toxicology Speciality Section and RSC Toxicology Group]</p>	<p>Symposium 2 (Space 4&5 – Level 12): Female Reprotox Regulatory Needs: from <i>in vivo</i> to NAM developments <i>Organised by: Dr Miriam Jacobs (UK HSA)</i> <i>Chairs: Dr Matt Van de Pette (UK HSA) and Ms Gabrielle Oxley (MRC Toxicology Unit)</i> [Hosted by Regulatory Toxicology Speciality Section]</p>
<p>Symposium 1 (Space 1&2 – Level 13): <i>In silico</i> paths to chemical safety assessment <i>Chairs: Dr Ovnair Sepai (RSC Tox/UK HSA) and Prof. Andreas Bender (BTS/Cambridge University/Pangea Botanica)</i> [Collaboration between the Computational and In Silico Toxicology Speciality Section and RSC Toxicology Group]</p>	<p>Symposium 2 (Space 4&5 – Level 12): Female Reprotox Regulatory Needs: from <i>in vivo</i> to NAM developments <i>Organised by: Dr Miriam Jacobs (UK HSA)</i> <i>Chairs: Dr Matt Van de Pette (UK HSA) and Ms Gabrielle Oxley (MRC Toxicology Unit)</i> [Hosted by Regulatory Toxicology Speciality Section]</p>		
15:00 – 15:30	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> <p>In silico approaches for regulatory assessments: applying the lessons learned from developing (Q)SAR models to enhance assessments for complex endpoints (Dr Robert Foster, Lhasa)</p> </td> <td style="width: 50%; padding: 5px;"> <p>Reproductive toxicity: Facing challenges with using alternative test methods for predicting adverse outcomes (Prof. Terje Svingen, DTU, Denmark)</p> </td> </tr> </table>	<p>In silico approaches for regulatory assessments: applying the lessons learned from developing (Q)SAR models to enhance assessments for complex endpoints (Dr Robert Foster, Lhasa)</p>	<p>Reproductive toxicity: Facing challenges with using alternative test methods for predicting adverse outcomes (Prof. Terje Svingen, DTU, Denmark)</p>
<p>In silico approaches for regulatory assessments: applying the lessons learned from developing (Q)SAR models to enhance assessments for complex endpoints (Dr Robert Foster, Lhasa)</p>	<p>Reproductive toxicity: Facing challenges with using alternative test methods for predicting adverse outcomes (Prof. Terje Svingen, DTU, Denmark)</p>		
15:30 – 16:00	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> <p>Next Generation Risk Assessment for Occupational Chemical Safety – a Real World Example (Dr Adam Wood, Unilever)</p> </td> <td style="width: 50%; padding: 5px;"> <p>Models of murine female reproductive toxicity: Oocyte models (Dr Mat Van de Pette, UK HSA)</p> </td> </tr> </table>	<p>Next Generation Risk Assessment for Occupational Chemical Safety – a Real World Example (Dr Adam Wood, Unilever)</p>	<p>Models of murine female reproductive toxicity: Oocyte models (Dr Mat Van de Pette, UK HSA)</p>
<p>Next Generation Risk Assessment for Occupational Chemical Safety – a Real World Example (Dr Adam Wood, Unilever)</p>	<p>Models of murine female reproductive toxicity: Oocyte models (Dr Mat Van de Pette, UK HSA)</p>		
16:00 – 16:30	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> <p>Accelerating the development and impact of new approach methodologies (NAMs) in chemical safety assessment (Dr Natalie Burden, NC3Rs)</p> </td> <td style="width: 50%; padding: 5px;"> <p>The SAFER project: human models for females: Ovaries and early embryos, using advanced tissue and cell culture systems to develop new assays that can predict chemical toxicity toward reproduction Virtual presentation (Dr Paulina Damdidopoulou, Karolinska Institute, Sweden)</p> </td> </tr> </table>	<p>Accelerating the development and impact of new approach methodologies (NAMs) in chemical safety assessment (Dr Natalie Burden, NC3Rs)</p>	<p>The SAFER project: human models for females: Ovaries and early embryos, using advanced tissue and cell culture systems to develop new assays that can predict chemical toxicity toward reproduction Virtual presentation (Dr Paulina Damdidopoulou, Karolinska Institute, Sweden)</p>
<p>Accelerating the development and impact of new approach methodologies (NAMs) in chemical safety assessment (Dr Natalie Burden, NC3Rs)</p>	<p>The SAFER project: human models for females: Ovaries and early embryos, using advanced tissue and cell culture systems to develop new assays that can predict chemical toxicity toward reproduction Virtual presentation (Dr Paulina Damdidopoulou, Karolinska Institute, Sweden)</p>		
16:30 – 16:45	Symposia Reflection and Discussion		
16:45 – 17:10	<i>Refreshments (The Axis – Level 13; The Atrium – Level 12), Posters & Trade Exhibition (Spaces 7, 8 & 9)</i>		
17:10 – 17:40	Equality, Diversity and Inclusion – Inclusive Labs (Space 1&2 – Level 13) <i>Dr Katherine Deane</i> <i>Associate Professor in Research and Access Ambassador, University of East Anglia, UK</i>		

This meeting is supported by donations or purchase of exhibition space by the companies listed in the congress App and is limited to meeting the cost of the meeting, with no input into the scientific programme. The overall program has been designed based on the principles of Equality, Diversity and Inclusion. However, depending on the symposia which delegates select to attend, some apparent imbalance from an EDI perspective may be observed.

	Chair: Prof. Winston Morgan (University of East London)
17:40 – 18:25	Kevin Park (Mid Career) Achievement Award (Space 1&2 – Level 13): Dr Dominic Williams, Senior Director, Hepatic Safety at AstraZeneca, UK <i>Chair: Prof. Ian Copple (University of Liverpool)</i>
18:25 onwards	Drinks Reception - The Atrium <i>BTS Exec Committee Members will be identified by their congress badges and invite members to ask questions, provide feedback, and make suggestions – it's your society!</i>
19:00 – 21:00	Early Career Networking Session – Spaces 4 & 5

This meeting is supported by donations or purchase of exhibition space by the companies listed in the congress App and is limited to meeting the cost of the meeting, with no input into the scientific programme. The overall program has been designed based on the principles of Equality, Diversity and Inclusion. However, depending on the symposia which delegates select to attend, some apparent imbalance from an EDI perspective may be observed.

TUESDAY 16th April 2024			
08:00 – 08:45	BTS Ambassadors Breakfast – Wolfson Lecture Theatre (take self-service breakfast provided by venue)		
08:00	Registration opens – light breakfast items (fruit and pastries) will be available.		
	Symposium 3 (<i>Space 1&2 – Level 13</i>): Title: Risk assessment in practice -the challenge of difficult, ubiquitous and untested chemicals <i>Chairs: Dr Susy Brescia (HSE) & Prof. Martin Clift (Swansea University)</i> [Hosted by Risk Assessment Speciality Section]		Symposium 4 (<i>Space 4&5 – Level 12</i>): Title: Risk Assessment of Psychedelic drugs <i>Chairs: Dr Francisco Inesta-Vaquera (University of Extremadura, Spain) & Dr Carolin Schramm (Sanofi, UK)</i> [Hosted by Mechanistic and Discovery Toxicology Speciality Section]
09:00 – 09:30	Current understanding of inhaled MNPs (micro-nano plastics) in vivo (Dr Cyrill Bussy, Manchester University, UK)	09:00-09:25	Development of psychedelic drugs: from pharmacology to adverse effects/tox (Prof Jo Neill, University of Manchester)
09:30 – 10:00	Bioaerosol risk assessment and regulation: Challenges and progress for environmental, occupational and public health (Dr. Pippa Douglas, UK Environment Agency)	09:25-09:50	Regulatory aspects for psychedelic drug development – non-clinical considerations (David R Jones, Consultant Pharmacotoxicologist) Virtual presentation
10:00 – 10:30	The human health risk assessment of PFOA using NAMs (Dr Arthur de Carvalho e Silva, Birmingham University, UK)	09:50-10:15	Regulatory aspects for psychedelic drug development – clinical considerations (Dr Kirsty Wydenbach, Weatherden)
10:30 – 10:45	Oral Communication – Microplastic Toxicity and Translocation in Alveoli: Impact of Corona Formation (Ms Polyxeni (Jenny) Katsouli, Imperial College London)	10:15-10:40	The clinical toxicology of ketamine – acute and chronic patterns of toxicity Virtual presentation (Prof Paul Dargan, King’s College London)
10:45 – 11:00	<i>Symposia Reflection & Discussion Session</i>	10:40-11:00	<i>Symposia Reflection & Discussion Session</i>
11:00 – 11:25	Refreshments (<i>The Axis – Level 13; The Atrium – Level 12</i>), Posters & Trade Exhibition (Spaces 7, 8 & 9) BTS Poster Communications Judging		
	Symposium 5 (<i>Space 1&2 – Level 13</i>): Advances in Persistence and Bioaccumulation Assessment <i>Chairs: Dr. Natalie Burden (NC3Rs) and Dr. Paula Garcia (Corteva Agriscience)</i> [Hosted by: Ecotoxicology Speciality Section]		Symposium 6 (<i>Space 4&5 – Level 12</i>): Nonclinical Development of Complex Medical Products <i>Chair : Dr Keith McLuckie (Cell and Gene Therapy Catapult, UK)</i> [Hosted by: Translational Toxicology – Nonclinical Development Strategies for Medical Products Speciality Section]
11:25 – 11:55	Impacts of Sample Storage and Reference Compounds in the OECD 309 Surface Water Mineralisation Test (Mr Chris Hughes, Ricardo)		Translation of Toxicology Data to Clinical Dosing (Prof. Paul Baldrick, Fortrea Inc)
11:55 – 12:25	Regulatory and Industry Acceptance of New Approach Methodologies in Bioaccumulation Assessment (Dr Pippa Curtis Jackson, UK Environment Agency)		Case study of a cell therapy for Huntington’s disease (Prof. Anne Rosser, Cardiff University, UK)
12:25 – 12:55	An IATA for B assessment (Dr Michelle Embry, HESI)		Translational Safety – a pharmaceutical R&D strategy with huge potential (Dr Steffen Ernst, Apconix, UK)
12:55 – 13:10	<i>Symposia Reflection & Discussion Session</i>		<i>Symposia Reflection and Discussion</i>
13:10 – 14:05	Lunch (<i>The Axis – Level 13; The Atrium – Level 12</i>), Posters & Trade Exhibition (Spaces 7, 8 & 9) BTS Poster Communications Judging		

This meeting is supported by donations or purchase of exhibition space by the companies listed in the congress App and is limited to meeting the cost of the meeting, with no input into the scientific programme. The overall program has been designed based on the principles of Equality, Diversity and Inclusion. However, depending on the symposia which delegates select to attend, some apparent imbalance from an EDI perspective may be observed.

BTS Selected Short Oral Communications Hosted by the BTS Network for Early Stage Toxicologists (NEST)		
	<i>Chairs: Barbara Kubičková (Syngenta) & Kostas Papikinos (Imperial Brands) (Space 1&2 – Level 13)</i>	<i>Chairs: Emma Quartermain (UKHSA) & Georgia Reynolds (Unilever) (Space 4&5 – Level 12)</i>
14:05 – 14:20	Gabrielle Oxley (University of Cambridge/UKHSA) Using in vitro models for developmental and reproductive toxicology (DART) testing of epigenetic-modifying pharmaceutical drugs	Katy Wilson (Unilever) Application of an integrated approach using New Approach Methodologies (NAMs) for developmental and reproductive toxicity (DART) Next Generation Risk Assessment (NGRA)
14:20 – 14:35	Jessica Bosak (MRC Mitochondrial Biology Unit) Complex I inhibition as a mechanism in drug-induced liver injury	Emma Quartermain (UKHSA) Validation: Test method augmentation of a new non-animal test method for assessing metabolism of chemicals based on CYP450 enzyme induction
14:35 – 14:50	Laura Booth (Newcastle University) Using induced-pluripotent stem cell (iPSC)-derived cardiomyocytes to investigate the role of senescence in anthracycline-induced cardiotoxicity	Sophie Cable (Unilever) Assessing the protectiveness and utility of a NAM-based approach to safety decision making
14:50 – 15:05	Odara Medagedara (MRC Toxicology Unit) A multimodal in situ characterization of alveoli and submucosal glands in healthy and toxicant-induced damaged states	Zhou Yufeng (University of Liverpool) From Lab to Bedside: Assessing the Clinical Utility of Paper Arrow-Mass Spectrometry for Salivary Paracetamol
15:05 – 15:20	Jasper Komen (AstraZeneca) Implementation of CRISPR KO in HSPCs to investigate haematotoxicity target safety liabilities in vitro	Issa Rahaf (University of Manchester) Assessment of nanoplastic toxicity using human lung organoids enriched with macrophages
15:20 – 15:35	Chris Godbehere (MRC Toxicology Unit) Primary Ciliary Dyskinesia lung disease model reveals airway cells with altered barrier function, abnormal cilia morphology, and reduced capacity to respond to oxidative stress induced by particulate matter (PM2.5) exposure	Dimitrios Kakavas (Dublin City University) The impact of environmentally relevant coronas on nanotoxicity
15:35 – 16:00	<i>Refreshments (The Axis & The Atrium), Posters & Trade Exhibition (Spaces 7, 8 & 9)</i>	
15:35 – 16:00	BTS Poster Communications Judging	
16:00 – 16:45	ASCEPT Invitation Lecture (Space 1&2 – Level 13): When basic science informs clinical toxicology practice Dr Darren Roberts (New South Wales Poisons Information Centre, Australia) <i>Chair: Dr Lesley Reeve (Fortrea)</i>	
16:45 – 17:30	BTS Speciality Sections Discussions: Discussions on future activities and possible meeting topics for the speciality sections - led by the section Co-ordinators – <i>Open to All delegates</i> Clinical and Human Toxicology [Level 12 – Space 5] Computational and In silico Toxicology [Level 12 – Space 6] Ecotoxicology [Level 12 – Space 4] Mechanistic and Discovery Toxicology [Level 12 - Woolfson Lecture Theatre] Regulatory Toxicology – <i>meeting to be held outside of Congress dates</i> Risk Assessment [Level 12 – The Axis] Translational Toxicology – New Medical Products [Level 13 – Spaces 1&2]	
17:30 – 18:30	BTS: Paton Prize Lecture (Space 1&2 – Level 13): Embracing innovative toxicological science to transform regulatory assessments of chemical safety (Dr Julia Fentem, MBE, Unilever, UK) <i>Chair: Dr Phil Botham (Syngenta)</i>	
19:30 – 20:00	Delegate Networking and Congress Dinner Drinks Reception (Level 12 - The Atrium)	
20:00 – 00:00	Congress Dinner (Level 13 – Spaces 1&2) & Entertainment (Level 13 – The Axis)	

This meeting is supported by donations or purchase of exhibition space by the companies listed in the congress App and is limited to meeting the cost of the meeting, with no input into the scientific programme. The overall program has been designed based on the principles of Equality, Diversity and Inclusion. However, depending on the symposia which delegates select to attend, some apparent imbalance from an EDI perspective may be observed.

WEDNESDAY 17th April 2024			
08:00	Registration opens – light breakfast items (fruit and pastries) will be available.		
08:00 – 08:50	Breakfast meeting open to all - The advantages of being a Reviewer for the <i>Tox Res</i> journal Wolfson Lecture Theatre		
	Symposium 7 (<i>Space 1&2 – Level 13</i>): Medicines Safety <i>Chair: Dr James Coulson (Cardiff University, UK)</i> [Hosted by: Clinical & Human Toxicology Speciality Section]	BTS Study Director Workshop (<i>Space 4&5 – Level 12</i>): Organised by Mr Warren Harvey (ICON plc) and Mr James Sawyers (LabCorp)	
09:00 – 09:30	Pharmacogenomics of adverse drug reactions (Prof. Sir Munir Pirmohamed, University of Liverpool)	09:00-09:25	IV infusion in mice repro studies (Mr Hans vanWijk, LabCorp Drug Development)
09:30 – 10:00	Immunopharmacology (Prof. Dean Naisbitt, University of Liverpool)	09:25-09:50	The ins and outs of rodent lung fibrosis models (Dr Pan Filis, Charles River Laboratories)
10:00 – 10:30	Clinical presentations and management of adverse drug reactions (Dr Laurence Gray, Cardiff & Vale University Health Board)	09:50-10:15	Investigation of antimalarial drugs and their impact on oxidative stress within hepatocyte cell models (Mr Benjamin Park, Cyprotex)
		10:15-10:40	Novel Autologous Vessel & Vascularised Tissue-on-a-Chip Technology for the Hazard Identification and Immunotoxicology of Drugs and Therapies During Early Development (Dr Daniel Thwaites, LabCorp Drug Development)
10:30 – 10:45	Symposia Reflection and Discussion	10:40-10:45	Workshop Reflection and Discussion
10:45 – 11:15	Refreshments, Posters & Trade Exhibition Spaces 7, 8 & 9		
	Symposium 8 (<i>Space 1&2 – Level 13</i>): Preclinical Models and New Modalities - a mechanistic focus MRC ITTP Biannual Symposium <i>Chairs: Prof Marion MacFarlane & Dr Kirsti Hornigold (MRC Toxicology Unit)</i>	Symposium 9 (<i>Space 4&5 – Level 12</i>): The Pathology Perspective: Unraveling Complexity Through A Potpourri of Cases and Insights <i>Chair: Dr Catherine Ross</i> [Supported by British Society of Toxicological Pathology]	
11:15 – 11:45	From stress adaptation to off-target immune responses: the physiological consequences of modified mRNA in therapeutics (Prof. Anne Willis, MRC Toxicology Unit)	Carcinogenicity assessment: how toxicologists and pathologists can make the most of the opportunities of the ICHS1B addendum (Dr Richard Haworth, RosettaPath Ltd, UK)	
11:45 – 12:15	Functional and Mechanistic Safety Profiling of Targeted Protein Degraders (Dr Kevin Moreau, AstraZeneca)	Valvular heart disease associated with psychedelic and other drugs (Dr Peter Clements, GSK, UK)	
12:15 – 12:45	In silico Approaches for Risk Assessment of Small Molecules (Dr David Rouquie, Bayer)	Circumventing the immunogenicity barrier of CRISPR-Cas9 to achieve safer and efficient gene editing in vivo (Dr Rakesh Chandode, AstraZeneca, Sweden)	
12:45 – 13:00	Symposia Reflection and Discussion	Symposia Reflection and Discussion	
13:00 – 13:15	Close of Congress <i>Chairs of Symposium 8 and 9 to close the congress on behalf of the BTS</i>		
13:15 -	Lunch – to Eat-In, to extend networking opportunities, or to Take Away (boxes will be provided by venue)		

This meeting is supported by donations or purchase of exhibition space by the companies listed in the congress App and is limited to meeting the cost of the meeting, with no input into the scientific programme. The overall program has been designed based on the principles of Equality, Diversity and Inclusion. However, depending on the symposia which delegates select to attend, some apparent imbalance from an EDI perspective may be observed.